Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $4.00 at The Goldman Sachs Group
Silence Therapeutics (NASDAQ:SLN – Free Report) had its price target trimmed by The Goldman Sachs Group from $6.00 to $4.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a sell rating on the stock. Several other equities research analysts also recently weighed in on SLN. BMO Capital Markets reissued an “outperform” rating […]
Silence Therapeutics (NASDAQ:SLN – Free Report) had its price target trimmed by The Goldman Sachs Group from $6.00 to $4.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a sell rating on the stock. Several other equities research analysts also recently weighed in on SLN. BMO Capital Markets reissued an “outperform” rating […]
